• Return to Headlines

Allergan Plc has the Highest EBITDA Growth in the Pharmaceuticals Industry (AGN, ANIP, LLY, SUPN, MRK)

By Shiri Gupta

Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Allergan Plc ranks highest with a EBITDA growth of 354.9%. Following is Ani Pharmaceutic with a EBITDA growth of 90.3%. Eli Lilly & Co ranks third highest with a EBITDA growth of 60.9%.

Supernus Pharmac follows with a EBITDA growth of 59.4%, and Merck & Co rounds out the top five with a EBITDA growth of 58.9%.

SmarTrend recommended that its subscribers protect gains by selling shares of Supernus Pharmac on December 6th, 2018 by issuing a Downtrend alert when the shares were trading at $39.84. Since that call, shares of Supernus Pharmac have fallen 9.8%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: highest ebitda growth allergan plc ani pharmaceutic eli lilly & co supernus pharmac Merck & Co

Ticker(s): AGN ANIP LLY SUPN MRK